Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome

Experimental Hematology

Volumn 44, Issue 5, 2016, Pages 390-398

  Vaught, Arthur J ^a   Gavriilaki, Eleni ^a   Hueppchen, Nancy ^a   Blakemore, Karin ^a   Yuan, Xuan ^a   Seifert, Sara M ^a   York, Sarah ^a   Brodsky, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CELL KILLING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT INHIBITION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; YOUNG ADULT; ANALYSIS OF VARIANCE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PREGNANCY;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; HELLP SYNDROME; HUMANS; PREGNANCY; YOUNG ADULT;

EID: 84963600144     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.01.005     Document Type: Article

References (41)

1. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: Executive summary. Obstet Gynecol 2013, 122:1122-1131.
2. Chen X.K., Wen S.W., Smith G.N., Yang Q., Walker M.C. New-onset hypertension in late pregnancy and fetal growth: Different associations between singletons and twins. Hypertens Pregnancy 2007, 26:259-272.
3. Iacobelli S., Bonsante F., Robillard P.Y. Pre-eclampsia and preterm birth in Reunion Island: A 13 years cohort based study. Comparison with international data. J Matern Fetal Neonatal Med 2015, 1-22.
4. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982, 142:159-167.
5. Sibai B.M., Taslimi M.M., el-Nazer A., Amon E., Mabie B.C., Ryan G.M. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986, 155:501-509.
6. Martin J.N., Rinehart B.K., May W.L., Magann E.F., Terrone D.A., Blake P.G. The spectrum of severe preeclampsia: Comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999, 180:1373-1384.
7. Audibert F., Friedman S.A., Frangieh A.Y., Sibai B.M. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996, 175:460-464.
8. Sibai B.M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004, 103:981-991.
9. Fanaroff A.A., Stoll B.J., Wright L.L., et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007, 196:147.e1-147.e8.
10. Fitzpatrick K.E., Hinshaw K., Kurinczuk J.J., Knight M. Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome. Obstet Gynecol 2014, 123:618-627.
11. Martin J.N., Rose C.H., Briery C.M. Understanding and managing HELLP syndrome: The integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006, 195:914-934.
12. Uzan J., Carbonnel M., Piconne O., Asmar R., Ayoubi J.M. Pre-eclampsia: Pathophysiology, diagnosis, and management. Vasc Health Risk Manag 2011, 7:467-474.
13. Fang C.J., Richards A., Liszewski M.K., Kavanagh D., Atkinson J.P. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 2008, 143:336-348.
14. Haeger M., Unander M., Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1990, 76:698-702.
15. Burwick R.M., Fichorova R.N., Dawood H.Y., Yamamoto H.S., Feinberg B.B. Urinary excretion of C5b-9 in severe preeclampsia: Tipping the balance of complement activation in pregnancy. Hypertension 2013, 62:1040-1045.
16. Salmon J.E., Heuser C., Triebwasser M., et al. Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. PLoS Med 2011, 8:e1001013.
17. Cataland S.R., Wu H.M. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014, 28:67-74.
18. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
19. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.
20. Brodsky R.A., Young N.S., Antonioli E., et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111:1840-1847.
21. Legendre C.M., Licht C., Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 369:1379-1380.
22. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
23. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013, 34:201-203.
24. Gavriilaki E., Yuan X., Ye Z., et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015, 125:3637-3646.
25. Ham T.H., Dingle J.H. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: Certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Invest 1939, 18:657-672.
26. Brodsky R.A. Complement in hemolytic anemia. Blood 2015, 126:2459-2465.
27. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria. Blood 2014, 124:2804-2811.
28. Risitano A.M., Notaro R., Pascariello C., et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119:6307-6316.
29. Cataland S.R., Holers V.M., Geyer S., Yang S., Wu H.M. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014, 123:3733-3738.
30. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31:E1445-E1460.
31. Kavanagh D., Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431-2442.
32. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
33. Fakhouri F., Roumenina L., Provot F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
34. Kelly R.J., Höchsmann B., Kulasekararaj A., et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. NEJM 2015, 373:1032-1039.
35. Patriquin C., Leber B. Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: Case report and review of the literature. Clin Case Rep 2015, 3:88-91.
36. Hallstensen R.F., Bergseth G., Foss S., et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015, 220:452-459.
37. Danilov A.V., Brodsky R.A., Craigo S., Smith H., Miller K.B. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 2010, 34:566-571.
38. Ardissino G., Wally Ossola M., Baffero G.M., Rigotti A., Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013, 122:487-489.
39. Canigral C., Moscardo F., Castro C., et al. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 2014, 93:1421-1422.
40. Sarris I., Gandhi S., Koumis A., Elebute M., Shehata H., Penna L. Pregnancy outcome and safety of breast-feeding in two patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with eculizumab. Arch Dis Child Fetal Neonatal Ed 2012, 97:A119.
41. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K., et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 111:624-632.